- +1-315-215-1633
- sales@thebrainyinsights.com
The global liquid biopsy market was valued at USD 10.85 billion in 2023, increasing at a CAGR of 11.61% from 2024 to 2033 and anticipated to reach USD 32.54 billion by 2033. Asia-Pacific is expected to grow the fastest during the forecast period. The increasing awareness about the availability of various non-invasive treatments is anticipated to drive market growth.
Liquid biopsy is the sampling and analyzing of blood, saliva, or other bodily fluid. A liquid biopsy allows asymptomatic screening before the patient has cancer symptoms and is a non-invasive testing method for finding cancer at the early stages. After or during therapy, a small number of cancer cells usually stay in the patient's blood, named minimal residual disease. Oncology liquid biopsy and next-generation sequencing can glimpse minute numbers of cancer cells & determine whether the therapy has wholly eradicated cancer. Minimal residual disease detected by liquid biopsy can also be utilized to track the effectiveness of therapy and adjust the treatment the patient receives. Compared to liquid biopsy, tissue biopsy is less pushy and, thus, can be executed frequently over time to get a longitudinal outlook of cancer progression.
A liquid biopsy is a blood test to assess circulating tumor DNA (ctDNA) in the patient's bloodstream. Liquid biopsy has broad application possibilities in the diagnosis & treatment of cancer, including tumor heterogeneity, early diagnosis screening, drug resistance, and establishment of targets. A liquid biopsy, or fluid phase biopsy, is the analysis and sampling of non-solid biological tissue, especially blood. Liquid biopsy has the benefits of being non-invasive, precise, rapid, and particularly real-time. It can also overcome the heterogeneity of tumors & may replace tissue biopsy in the future. Multiple body fluids have been shown to have genetic material derived from tumors, such as saliva, blood, urine, stool, and cerebrospinal fluid (CSF). Liquid biopsies can have various functions: it can be used to diagnose physiological situations and inflammatory processes. In particular, it represents a valuable and practical minimally invasive tool for analyzing tumor-derived materials. Liquid biopsy is currently utilized as an alternative or complementary method to surgical biopsy. It means a non-invasive detection tool that overcomes systematic problems in the clinical evaluation of tumors, which derives from the absence of accessibility to tumor tissue and its clonal heterogeneity. Liquid biopsy describes a promising tool for early cancer detection. It could advance significantly as a diagnostic tool for different cancers, including melanoma, ovary, breast, lung, colorectal, stomach, liver, and pancreas. Liquid biopsies could be utilized as an alternative to tumor biopsies to evaluate predictive biomarkers & responses to therapy, and there are multiple new studies assessing the clinical effects of this new technique.
Get an overview of this study by requesting a free sample
For example, in July 2021, Biocept Company was awarded a South Korean Patent for its Primer-Switch technology that catches rare mutations in circulating tumor DNA utilizing real-time PCR & associated investigation methods.
The increasing cancer prevalence: Radiologists play a crucial role in cancer care via imaging for screening, treatment planning, diagnosis, and surveillance. In addition, radiologists' image-guided tissue biopsies permit more specific diagnoses and the ability to characterize tumor cells molecularly. Radiologists are implicated in cancer therapy as interventional radiologists deliver minimally invasive local-regional treatments, and nuclear medicine physicians administer radionuclide treatment. Liquid biopsy typically affects obtaining blood from a peripheral venous site like the median cubital vein. The raised adoption of liquid biopsy in cancer is owing to its potential for non-invasive detection of targeted genomic alteration in parallel to targeted treatment. Non-cancerous application of liquid biopsy contains a diagnosis of heart attack & atherosclerosis. Advancement in next-generation sequencing (NGS) for patients with advanced stages of cancer is propelling market growth.
The lower sensitivity of certain liquid biopsies: The liquid biopsy samples primarily contain normal DNA. Clinical sensitivity presents a challenge to liquid biopsy because circulating tumor DNA is rare compared to hematological molecules in a blood sample. Also, small-scale enterprises are hampered by a lack of trained personnel to manage the systems.
Advantages of liquid biopsy technology: The current applicability in the non-availability of tissue sections for conventional biopsy approaches is the opportunity factor for market growth. Further, the growing number of ongoing clinical trials for developing innovative solutions is the market growth. Also, several benefits associated with liquid biopsies, like improved precision, less invasive nature, and post-treatment monitoring, propel market growth.
The lack of clinical utility: The lack of large-scale clinical trials demonstrating liquid biopsy's clinical utility hamper the market growth.
The regions analyzed for the market include Europe, South America, Asia Pacific, North America, the Middle East, and Africa. North America emerged as the largest market for the global liquid biopsy market, with a 48.11% share of the market revenue in 2023. North America dominates the liquid biopsy market due to the creation of reimbursement and regulatory policies for NGS-based diagnostic tools. Furthermore, the increasing demand for non-invasive disease diagnosis and continuous product launches with a high focus on R&D by the market players are also helping to boost the market growth in this region. Apart from this, the increasing government investments in infrastructural developments, urbanization, and IT and telecommunications infrastructure development are helping to boost the market growth in this region during the forecast period. However, the Asia Pacific is expected to grow the fastest during the forecast period due to the increasing awareness related to the use of liquid biopsy and the increase in healthcare expenditure. In addition, the rising number of cancer cases and vital R&D initiatives from the key player are helping to propel the market growth in the region. Further, the several acquisitions and the opening of new sites, increased facilitators for diagnosis of cancer, the growing number of blood donation activities, and the adoption of innovative & advanced technology are also helping to boost the market growth.
North America Region Liquid Biopsy Market Share in 2023 - 48.11%
www.thebrainyinsights.com
Check the geographical analysis of this market by requesting a free sample
The biomarker types segment is divided into circulating tumor DNA (CTDNA), circulating tumor cells (CTCs), extracellular vesicles (EVS), and others. The circulating tumor DNA (CTDNA) segment dominated, with a market share of 32.03% in 2023. This growth is attributed to the rising demand for cancer diagnoses as well as improved government funding. Further, the circulating tumor DNA is a promising biomarker for ovarian cancer and can be detected utilizing a non-invasive liquid biopsy. An expansive variety of circulating tumor DNA applications are being elucidated in numerous studies for tracking ovarian carcinoma during diagnostic & prognostic evaluations of patients and are being incorporated into clinical trials to assess the disease. Apart from this, by 2030, the circulating tumor cells (CTCs) segment will likely dominate the market due to technological advancements in chip technology.
The sample segment is divided into the urine sample, blood sample, and others. In 2023, the blood sample segment dominated the market with the largest market share of 42.11%. This growth is attributed to the mounting number of accident & trauma cases.
The end-user segment is divided into academic and research centers, hospitals and laboratories, and others. In 2023, the hospitals and laboratories segment dominated the market with the largest market share of 41.21%. This growth is attributed to the increasing disposable income, urbanization, and awareness of the need to prevent major illnesses.
The technology segment is divided into single-gene analysis (PCR Microarrays) and multi-gene-parallel analysis (NGS). In 2023, the multi-gene-parallel analysis (NGS) segment dominated the market, accounting for around 56.09% of global revenue. This growth is attributed to the increased incidence of lung cancer, melanoma, breast cancer, ovarian cancer, and others. NGS can be used for transcriptome sequencing (RNA sequencing), exome sequencing, whole-genome sequencing, and targeted sequencing of multigene panels. Further, by 2030, the single gene analysis (PCR Microarrays) segment will likely dominate the market due to the growing demand for point-of-care tests and self-tests.
Report Description:
| Attribute | Description |
|---|---|
| Market Size | Revenue (USD Billion) |
| Market size value in 2023 | USD 10.85 Billion |
| Market size value in 2033 | USD 32.54 Billion |
| CAGR (2024 to 2033) | 11.61% |
| Historical data | 2020-2022 |
| Base Year | 2023 |
| Forecast | 2024-2033 |
| Region | The key regions are Europe, North America, Asia Pacific, South America, and Middle East & Africa. |
| Segments | Key Segments are biomarker types, sample, end-user, technology, and regions |
As per The Brainy Insights, the size of the liquid biopsy market was valued at USD 10.85 billion in 2023 to USD 32.54 billion by 2033.
Global liquid biopsy market is growing at a CAGR of 11.61% during the forecast period 2024-2033.
North America region emerged as the largest market for the liquid biopsy.
1. Introduction
1.1. Objectives of the Study
1.2. Market Definition
1.3. Research Scope
1.4. Currency
1.5. Key Target Audience
2. Research Methodology and Assumptions
3. Executive Summary
4. Premium Insights
4.1. Porter’s Five Forces Analysis
4.2. Value Chain Analysis
4.3. Top Investment Pockets
4.3.1. Market Attractiveness Analysis By Biomarker Types
4.3.2. Market Attractiveness Analysis By Sample
4.3.3. Market Attractiveness Analysis By End-User
4.3.4. Market Attractiveness Analysis By Technology
4.3.5. Market Attractiveness Analysis By Region
4.4. Industry Trends
5. Market Dynamics
5.1. Market Evaluation
5.2. Drivers
5.2.1. The increased research funding from national cancer institute
5.2.2. The rising aging population and cancer incidences
5.2.3. The rising applications of liquid biopsy
5.2.4. The rising sensitivity of detecting techniques and assays
5.3. Restraints
5.3.1. The lack of sensitivity and specificity of liquid biopsy tests
5.3.2. The stringent regulatory issues
5.4. Opportunities
5.4.1. The growing significance of companion diagnostics
5.5. Challenges
5.5.1. The uncertain reimbursement and regulatory policies
6. Global Liquid Biopsy Market Analysis and Forecast, By Biomarker Types
6.1. Segment Overview
6.2. Circulating Tumor DNA (CTDNA)
6.3. Circulating Tumor Cells (CTCs)
6.4. Extracellular Vesicles (EVS)
6.5. Others
7. Global Liquid Biopsy Market Analysis and Forecast, By Sample
7.1. Segment Overview
7.2. Urine Sample
7.3. Blood Sample
7.4. Others
8. Global Liquid Biopsy Market Analysis and Forecast, By End-User
8.1. Segment Overview
8.2. Academic and Research Centers
8.3. Hospitals and Laboratories
8.4. Others
9. Global Liquid Biopsy Market Analysis and Forecast, By Technology
9.1. Segment Overview
9.2. Single Gene Analysis (PCR Microarrays)
9.3. Multi-gene-parallel Analysis (NGS)
10. Global Liquid Biopsy Market Analysis and Forecast, By Regional Analysis
10.1. Segment Overview
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.2.3. Mexico
10.3. Europe
10.3.1. Germany
10.3.2. France
10.3.3. U.K.
10.3.4. Italy
10.3.5. Spain
10.4. Asia-Pacific
10.4.1. Japan
10.4.2. China
10.4.3. India
10.5. South America
10.5.1. Brazil
10.6. Middle East and Africa
10.6.1. UAE
10.6.2. South Africa
11. Global Liquid Biopsy Market-Competitive Landscape
11.1. Overview
11.2. Market Share of Key Players in Global Liquid Biopsy Market
11.2.1. Global Company Market Share
11.2.2. North America Company Market Share
11.2.3. Europe Company Market Share
11.2.4. APAC Company Market Share
11.3. Competitive Situations and Trends
11.3.1. Product Launches and Developments
11.3.2. Partnerships, Collaborations, and Agreements
11.3.3. Mergers & Acquisitions
11.3.4. Expansions
12. Company Profiles
12.1. CareDx Inc.
12.1.1. Business Overview
12.1.2. Company Snapshot
12.1.3. Company Market Share Analysis
12.1.4. Company Product Portfolio
12.1.5. Recent Developments
12.1.6. SWOT Analysis
12.2. Eurofins Scientific
12.2.1. Business Overview
12.2.2. Company Snapshot
12.2.3. Company Market Share Analysis
12.2.4. Company Product Portfolio
12.2.5. Recent Developments
12.2.6. SWOT Analysis
12.3. Exact Sciences Corporation
12.3.1. Business Overview
12.3.2. Company Snapshot
12.3.3. Company Market Share Analysis
12.3.4. Company Product Portfolio
12.3.5. Recent Developments
12.3.6. SWOT Analysis
12.4. Immucor, Inc.
12.4.1. Business Overview
12.4.2. Company Snapshot
12.4.3. Company Market Share Analysis
12.4.4. Company Product Portfolio
12.4.5. Recent Developments
12.4.6. SWOT Analysis
12.5. MDxHealth
12.5.1. Business Overview
12.5.2. Company Snapshot
12.5.3. Company Market Share Analysis
12.5.4. Company Product Portfolio
12.5.5. Recent Developments
12.5.6. SWOT Analysis
12.6. Menarini Silicon Biosystems
12.6.1. Business Overview
12.6.2. Company Snapshot
12.6.3. Company Market Share Analysis
12.6.4. Company Product Portfolio
12.6.5. Recent Developments
12.6.6. SWOT Analysis
12.7. GUARDANT HEALTH, INC
12.7.1. Business Overview
12.7.2. Company Snapshot
12.7.3. Company Market Share Analysis
12.7.4. Company Product Portfolio
12.7.5. Recent Developments
12.7.6. SWOT Analysis
12.8. Thermo Fisher Scientific Inc.
12.8.1. Business Overview
12.8.2. Company Snapshot
12.8.3. Company Market Share Analysis
12.8.4. Company Product Portfolio
12.8.5. Recent Developments
12.8.6. SWOT Analysis
12.9. Illumina, Inc.
12.9.1. Business Overview
12.9.2. Company Snapshot
12.9.3. Company Market Share Analysis
12.9.4. Company Product Portfolio
12.9.5. Recent Developments
12.9.6. SWOT Analysis
12.10. Genomic Health
12.10.1. Business Overview
12.10.2. Company Snapshot
12.10.3. Company Market Share Analysis
12.10.4. Company Product Portfolio
12.10.5. Recent Developments
12.10.6. SWOT Analysis
12.11. Myriad Genetics, Inc.
12.11.1. Business Overview
12.11.2. Company Snapshot
12.11.3. Company Market Share Analysis
12.11.4. Company Product Portfolio
12.11.5. Recent Developments
12.11.6. SWOT Analysis
12.12. RainDance Technologies Inc.
12.12.1. Business Overview
12.12.2. Company Snapshot
12.12.3. Company Market Share Analysis
12.12.4. Company Product Portfolio
12.12.5. Recent Developments
12.12.6. SWOT Analysis
12.13. QIAGEN
12.13.1. Business Overview
12.13.2. Company Snapshot
12.13.3. Company Market Share Analysis
12.13.4. Company Product Portfolio
12.13.5. Recent Developments
12.13.6. SWOT Analysis
12.14. Exosome Diagnostics
12.14.1. Business Overview
12.14.2. Company Snapshot
12.14.3. Company Market Share Analysis
12.14.4. Company Product Portfolio
12.14.5. Recent Developments
12.14.6. SWOT Analysis
12.15. Biocept, Inc
12.15.1. Business Overview
12.15.2. Company Snapshot
12.15.3. Company Market Share Analysis
12.15.4. Company Product Portfolio
12.15.5. Recent Developments
12.15.6. SWOT Analysis
12.16. LungLife AI, Inc.
12.16.1. Business Overview
12.16.2. Company Snapshot
12.16.3. Company Market Share Analysis
12.16.4. Company Product Portfolio
12.16.5. Recent Developments
12.16.6. SWOT Analysis
12.17. Natera, Inc.
12.17.1. Business Overview
12.17.2. Company Snapshot
12.17.3. Company Market Share Analysis
12.17.4. Company Product Portfolio
12.17.5. Recent Developments
12.17.6. SWOT Analysis
12.18. Trovagene
12.18.1. Business Overview
12.18.2. Company Snapshot
12.18.3. Company Market Share Analysis
12.18.4. Company Product Portfolio
12.18.5. Recent Developments
12.18.6. SWOT Analysis
12.19. F. Hoffmann-La Roche Ltd
12.19.1. Business Overview
12.19.2. Company Snapshot
12.19.3. Company Market Share Analysis
12.19.4. Company Product Portfolio
12.19.5. Recent Developments
12.19.6. SWOT Analysis
12.20. Bio-Rad Laboratories, Inc.
12.20.1. Business Overview
12.20.2. Company Snapshot
12.20.3. Company Market Share Analysis
12.20.4. Company Product Portfolio
12.20.5. Recent Developments
12.20.6. SWOT Analysis
List of Table
1. Global Liquid Biopsy Market, By Biomarker Types, 2020-2033 (USD Billion)
2. Global Circulating Tumor DNA (CTDNA), Liquid Biopsy Market, By Region, 2020-2033 (USD Billion)
3. Global Circulating Tumor Cells (CTCs), Liquid Biopsy Market, By Region, 2020-2033 (USD Billion)
4. Global Extracellular Vesicles (EVS), Liquid Biopsy Market, By Region, 2020-2033 (USD Billion)
5. Global Others, Liquid Biopsy Market, By Region, 2020-2033 (USD Billion)
6. Global Liquid Biopsy Market, By Sample, 2020-2033 (USD Billion)
7. Global Urine Sample, Liquid Biopsy Market, By Region, 2020-2033 (USD Billion)
8. Global Blood Sample, Liquid Biopsy Market, By Region, 2020-2033 (USD Billion)
9. Global Others, Liquid Biopsy Market, By Region, 2020-2033 (USD Billion)
10. Global Liquid Biopsy Market, By End-User, 2020-2033 (USD Billion)
11. Global Academic and Research Centers, Liquid Biopsy Market, By Region, 2020-2033 (USD Billion)
12. Global Hospitals and Laboratories, Liquid Biopsy Market, By Region, 2020-2033 (USD Billion)
13. Global Others, Liquid Biopsy Market, By Region, 2020-2033 (USD Billion)
14. Global Liquid Biopsy Market, By Technology, 2020-2033 (USD Billion)
15. Global Single Gene Analysis (PCR Microarrays), Liquid Biopsy Market, By Region, 2020-2033 (USD Billion)
16. Global Multi-gene-parallel Analysis (NGS), Liquid Biopsy Market, By Region, 2020-2033 (USD Billion)
17. North America Liquid Biopsy Market, By Biomarker Types, 2020-2033 (USD Billion)
18. North America Liquid Biopsy Market, By Sample, 2020-2033 (USD Billion)
19. North America Liquid Biopsy Market, By End-User, 2020-2033 (USD Billion)
20. North America Liquid Biopsy Market, By Technology, 2020-2033 (USD Billion)
21. U.S. Liquid Biopsy Market, By Biomarker Types, 2020-2033 (USD Billion)
22. U.S. Liquid Biopsy Market, By Sample, 2020-2033 (USD Billion)
23. U.S. Liquid Biopsy Market, By End-User, 2020-2033 (USD Billion)
24. U.S. Liquid Biopsy Market, By Technology, 2020-2033 (USD Billion)
25. Canada Liquid Biopsy Market, By Biomarker Types, 2020-2033 (USD Billion)
26. Canada Liquid Biopsy Market, By Sample, 2020-2033 (USD Billion)
27. Canada Liquid Biopsy Market, By End-User, 2020-2033 (USD Billion)
28. Canada Liquid Biopsy Market, By Technology, 2020-2033 (USD Billion)
29. Mexico Liquid Biopsy Market, By Biomarker Types, 2020-2033 (USD Billion)
30. Mexico Liquid Biopsy Market, By Sample, 2020-2033 (USD Billion)
31. Mexico Liquid Biopsy Market, By End-User, 2020-2033 (USD Billion)
32. Mexico Liquid Biopsy Market, By Technology, 2020-2033 (USD Billion)
33. Europe Liquid Biopsy Market, By Biomarker Types, 2020-2033 (USD Billion)
34. Europe Liquid Biopsy Market, By Sample, 2020-2033 (USD Billion)
35. Europe Liquid Biopsy Market, By End-User, 2020-2033 (USD Billion)
36. Europe Liquid Biopsy Market, By Technology, 2020-2033 (USD Billion)
37. Germany Liquid Biopsy Market, By Biomarker Types, 2020-2033 (USD Billion)
38. Germany Liquid Biopsy Market, By Sample, 2020-2033 (USD Billion)
39. Germany Liquid Biopsy Market, By End-User, 2020-2033 (USD Billion)
40. Germany Liquid Biopsy Market, By Technology, 2020-2033 (USD Billion)
41. France Liquid Biopsy Market, By Biomarker Types, 2020-2033 (USD Billion)
42. France Liquid Biopsy Market, By Sample, 2020-2033 (USD Billion)
43. France Liquid Biopsy Market, By End-User, 2020-2033 (USD Billion)
44. France Liquid Biopsy Market, By Technology, 2020-2033 (USD Billion)
45. U.K. Liquid Biopsy Market, By Biomarker Types, 2020-2033 (USD Billion)
46. U.K. Liquid Biopsy Market, By Sample, 2020-2033 (USD Billion)
47. U.K. Liquid Biopsy Market, By End-User, 2020-2033 (USD Billion)
48. U.K. Liquid Biopsy Market, By Technology, 2020-2033 (USD Billion)
49. Italy Liquid Biopsy Market, By Biomarker Types, 2020-2033 (USD Billion)
50. Italy Liquid Biopsy Market, By Sample, 2020-2033 (USD Billion)
51. Italy Liquid Biopsy Market, By End-User, 2020-2033 (USD Billion)
52. Italy Liquid Biopsy Market, By Technology, 2020-2033 (USD Billion)
53. Spain Liquid Biopsy Market, By Biomarker Types, 2020-2033 (USD Billion)
54. Spain Liquid Biopsy Market, By Sample, 2020-2033 (USD Billion)
55. Spain Liquid Biopsy Market, By End-User, 2020-2033 (USD Billion)
56. Spain Liquid Biopsy Market, By Technology, 2020-2033 (USD Billion)
57. Asia Pacific Liquid Biopsy Market, By Biomarker Types, 2020-2033 (USD Billion)
58. Asia Pacific Liquid Biopsy Market, By Sample, 2020-2033 (USD Billion)
59. Asia Pacific Liquid Biopsy Market, By End-User, 2020-2033 (USD Billion)
60. Asia Pacific Liquid Biopsy Market, By Technology, 2020-2033 (USD Billion)
61. Japan Liquid Biopsy Market, By Biomarker Types, 2020-2033 (USD Billion)
62. Japan Liquid Biopsy Market, By Sample, 2020-2033 (USD Billion)
63. Japan Liquid Biopsy Market, By End-User, 2020-2033 (USD Billion)
64. Japan Liquid Biopsy Market, By Technology, 2020-2033 (USD Billion)
65. China Liquid Biopsy Market, By Biomarker Types, 2020-2033 (USD Billion)
66. China Liquid Biopsy Market, By Sample, 2020-2033 (USD Billion)
67. China Liquid Biopsy Market, By End-User, 2020-2033 (USD Billion)
68. China Liquid Biopsy Market, By Technology, 2020-2033 (USD Billion)
69. India Liquid Biopsy Market, By Biomarker Types, 2020-2033 (USD Billion)
70. India Liquid Biopsy Market, By Sample, 2020-2033 (USD Billion)
71. India Liquid Biopsy Market, By End-User, 2020-2033 (USD Billion)
72. India Liquid Biopsy Market, By Technology, 2020-2033 (USD Billion)
73. South America Liquid Biopsy Market, By Biomarker Types, 2020-2033 (USD Billion)
74. South America Liquid Biopsy Market, By Sample, 2020-2033 (USD Billion)
75. South America Liquid Biopsy Market, By End-User, 2020-2033 (USD Billion)
76. South America Liquid Biopsy Market, By Technology, 2020-2033 (USD Billion)
77. Brazil Liquid Biopsy Market, By Biomarker Types, 2020-2033 (USD Billion)
78. Brazil Liquid Biopsy Market, By Sample, 2020-2033 (USD Billion)
79. Brazil Liquid Biopsy Market, By End-User, 2020-2033 (USD Billion)
80. Brazil Liquid Biopsy Market, By Technology, 2020-2033 (USD Billion)
81. Middle East and Africa Liquid Biopsy Market, By Biomarker Types, 2020-2033 (USD Billion)
82. Middle East and Africa Liquid Biopsy Market, By Sample, 2020-2033 (USD Billion)
83. Middle East and Africa Liquid Biopsy Market, By End-User, 2020-2033 (USD Billion)
84. Middle East and Africa Liquid Biopsy Market, By Technology, 2020-2033 (USD Billion)
85. UAE Liquid Biopsy Market, By Biomarker Types, 2020-2033 (USD Billion)
86. UAE Liquid Biopsy Market, By Sample, 2020-2033 (USD Billion)
87. UAE Liquid Biopsy Market, By End-User, 2020-2033 (USD Billion)
88. UAE Liquid Biopsy Market, By Technology, 2020-2033 (USD Billion)
89. South Africa Liquid Biopsy Market, By Biomarker Types, 2020-2033 (USD Billion)
90. South Africa Liquid Biopsy Market, By Sample, 2020-2033 (USD Billion)
91. South Africa Liquid Biopsy Market, By End-User, 2020-2033 (USD Billion)
92. South Africa Liquid Biopsy Market, By Technology, 2020-2033 (USD Billion)
List of Figures
1. Global Liquid Biopsy Market Segmentation
2. Global Liquid Biopsy Market: Research Methodology
3. Market Size Estimation Methodology: Bottom-Up Approach
4. Market Size Estimation Methodology: Top-Down Approach
5. Data Triangulation
6. Porter’s Five Forces Analysis
7. Value Chain Analysis
8. Global Liquid Biopsy Market Attractiveness Analysis By Biomarker Types
9. Global Liquid Biopsy Market Attractiveness Analysis By Sample
10. Global Liquid Biopsy Market Attractiveness Analysis By End-User
11. Global Liquid Biopsy Market Attractiveness Analysis By Technology
12. Global Liquid Biopsy Market Attractiveness Analysis By Region
13. Global Liquid Biopsy Market: Dynamics
14. Global Liquid Biopsy Market Share By Biomarker Types (2023 & 2033)
15. Global Liquid Biopsy Market Share By Sample (2023 & 2033)
16. Global Liquid Biopsy Market Share By End-User (2023 & 2033)
17. Global Liquid Biopsy Market Share By Technology (2023 & 2033)
18. Global Liquid Biopsy Market Share By Regions (2023 & 2033)
19. Global Liquid Biopsy Market Share By Company (2023)
This study forecasts revenue at global, regional, and country levels from 2020 to 2033. The Brainy Insights has segmented the global liquid biopsy based on below mentioned segments:
Global Liquid Biopsy Market by Biomarker Types:
Global Liquid Biopsy Market by Sample:
Global Liquid Biopsy Market by End-User:
Global Liquid Biopsy Market by Technology:
Global Liquid Biopsy by Region:
Research has its special purpose to undertake marketing efficiently. In this competitive scenario, businesses need information across all industry verticals; the information about customer wants, market demand, competition, industry trends, distribution channels etc. This information needs to be updated regularly because businesses operate in a dynamic environment. Our organization, The Brainy Insights incorporates scientific and systematic research procedures in order to get proper market insights and industry analysis for overall business success. The analysis consists of studying the market from a miniscule level wherein we implement statistical tools which helps us in examining the data with accuracy and precision.
Our research reports feature both; quantitative and qualitative aspects for any market. Qualitative information for any market research process are fundamental because they reveal the customer needs and wants, usage and consumption for any product/service related to a specific industry. This in turn aids the marketers/investors in knowing certain perceptions of the customers. Qualitative research can enlighten about the different product concepts and designs along with unique service offering that in turn, helps define marketing problems and generate opportunities. On the other hand, quantitative research engages with the data collection process through interviews, e-mail interactions, surveys and pilot studies. Quantitative aspects for the market research are useful to validate the hypotheses generated during qualitative research method, explore empirical patterns in the data with the help of statistical tools, and finally make the market estimations.
The Brainy Insights offers comprehensive research and analysis, based on a wide assortment of factual insights gained through interviews with CXOs and global experts and secondary data from reliable sources. Our analysts and industry specialist assume vital roles in building up statistical tools and analysis models, which are used to analyse the data and arrive at accurate insights with exceedingly informative research discoveries. The data provided by our organization have proven precious to a diverse range of companies, facilitating them to address issues such as determining which products/services are the most appealing, whether or not customers use the product in the manner anticipated, the purchasing intentions of the market and many others.
Our research methodology encompasses an idyllic combination of primary and secondary initiatives. Key phases involved in this process are listed below:
The phase involves the gathering and collecting of market data and its related information with the help of different sources & research procedures.
The data procurement stage involves in data gathering and collecting through various data sources.
This stage involves in extensive research. These data sources includes:
Purchased Database: Purchased databases play a crucial role in estimating the market sizes irrespective of the domain. Our purchased database includes:
Primary Research: The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. Primary research mainly involves in telephonic interviews, E-mail interactions and face-to-face interviews with the raw material providers, manufacturers/producers, distributors, & independent consultants. The interviews that we conduct provides valuable data on market size and industry growth trends prevailing in the market. Our organization also conducts surveys with the various industry experts in order to gain overall insights of the industry/market. For instance, in healthcare industry we conduct surveys with the pharmacists, doctors, surgeons and nurses in order to gain insights and key information of a medical product/device/equipment which the customers are going to usage. Surveys are conducted in the form of questionnaire designed by our own analyst team. Surveys plays an important role in primary research because surveys helps us to identify the key target audiences of the market. Additionally, surveys helps to identify the key target audience engaged with the market. Our survey team conducts the survey by targeting the key audience, thus gaining insights from them. Based on the perspectives of the customers, this information is utilized to formulate market strategies. Moreover, market surveys helps us to understand the current competitive situation of the industry. To be precise, our survey process typically involve with the 360 analysis of the market. This analytical process begins by identifying the prospective customers for a product or service related to the market/industry to obtain data on how a product/service could fit into customers’ lives.
Secondary Research: The secondary data sources includes information published by the on-profit organizations such as World bank, WHO, company fillings, investor presentations, annual reports, national government documents, statistical databases, blogs, articles, white papers and others. From the annual report, we analyse a company’s revenue to understand the key segment and market share of that organization in a particular region. We analyse the company websites and adopt the product mapping technique which is important for deriving the segment revenue. In the product mapping method, we select and categorize the products offered by the companies catering to domain specific market, deduce the product revenue for each of the companies so as to get overall estimation of the market size. We also source data and analyses trends based on information received from supply side and demand side intermediaries in the value chain. The supply side denotes the data gathered from supplier, distributor, wholesaler and the demand side illustrates the data gathered from the end customers for respective market domain.
The supply side for a domain specific market is analysed by:
The demand side for the market is estimated through:
In-house Library: Apart from these third-party sources, we have our in-house library of qualitative and quantitative information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, historic databases, internal audit reports and archives.
Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those cases, we use our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopt a robust research technique in order to produce the estimates:
Data Synthesis: This stage involves the analysis & mapping of all the information obtained from the previous step. It also involves in scrutinizing the data for any discrepancy observed while data gathering related to the market. The data is collected with consideration to the heterogeneity of sources. Robust scientific techniques are in place for synthesizing disparate data sets and provide the essential contextual information that can orient market strategies. The Brainy Insights has extensive experience in data synthesis where the data passes through various stages:
Market Deduction & Formulation: The final stage comprises of assigning data points at appropriate market spaces so as to deduce feasible conclusions. Analyst perspective & subject matter expert based holistic form of market sizing coupled with industry analysis also plays a crucial role in this stage.
This stage involves in finalization of the market size and numbers that we have collected from data integration step. With data interpolation, it is made sure that there is no gap in the market data. Successful trend analysis is done by our analysts using extrapolation techniques, which provide the best possible forecasts for the market.
Data Validation & Market Feedback: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helps us finalize data-points to be used for final calculations.
The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. The data validation interview and discussion panels are typically composed of the most experienced industry members. The participants include, however, are not limited to:
Moreover, we always validate our data and findings through primary respondents from all the major regions we are working on.
Free Customization
Fortune 500 Clients
Free Yearly Update On Purchase Of Multi/Corporate License
Companies Served Till Date
